Butylphthalide
ApprovedSmall molecule
Butylphthalide is one of 136 small molecule programs targeting Cognitive impairment. It is currently in Approved.
4
Indications
9
Total Trials
6
Active Trials
135
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Butylphthalide
PPeking Union Medical College Hospital
Approved
Activase
RochePreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Alka-Seltzer
AAbbott
Preclinical
Direct Anticoagulant
BayerPreclinical
Carbidopa-Levodopa
Neurocrine BiosciencesPreclinical
Botulinum Toxin a
GSKPreclinical
Anticoagulant
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke3 trials
Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
Completed·—·Phase 3·NCT03539445·1,216 enrolled
Stroke2 trials
Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
Not yet recruiting·—·Phase 3·NCT07252544·3,156 enrolled
Efficacy1 trial
Cognitive impairment1 trial
Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT07193277·220 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Butylphthalide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details